<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646891</url>
  </required_header>
  <id_info>
    <org_study_id>VAC-041</org_study_id>
    <nct_id>NCT02646891</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Trivalent P2-VP8 Subunit Rotavirus Vaccine in Adults, Toddlers and Infants</brief_title>
  <official_title>Phase I/II Double-blind, Randomized, Placebo-controlled, Descending Age, Dose-escalation Study of the Safety, and Immunogenicity of the Trivalent P2-VP8 Subunit Rotavirus Vaccine in Healthy South African Adults, Toddlers and Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Emmes Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is is a study of a parenteral trivalent rotavirus vaccine (P2-VP8 subunit rotavirus
      vaccine). The study examined the safety and immunogenicity of three dose levels of this
      vaccine in healthy South African adults, toddlers and infants. Progression from one dose
      level to another and to the next age group population was based on the assessment of safety
      information from the lowest dose and older age group.

      The primary safety hypothesis is that the P2-VP8 subunit rotavirus vaccine is safe and
      well-tolerated. The primary immunogenicity hypothesis is that the trivalent P2-VP8 subunit
      rotavirus vaccine is immunogenic in infant participants and will induce an immune response to
      at least 2 of the 3 strains in 60% or more of participants in at least one of the study
      groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The P2-VP8 vaccine tested in this study was developed by Dr. Taka Hoshino at National
      Institute of Allergy and Infectious Diseases (NIAID). The monovalent (P[8]) vaccine
      previously tested consisted of bacteria-expressed VP8 subunit from the Wa strain of human
      rotaviruses (G1[P8]). A deoxyribonucleic acid (DNA) segment encoding the sequence of P2
      epitope from tetanus toxin was fused to the VP8 sequence, resulting in this chimeric protein
      vaccine (P2-VP8). Dr. Hoshino's laboratory demonstrated in preclinical testing that the
      immunogenicity of these VP8 proteins could be significantly enhanced when fused with the P2
      epitope of tetanus toxin, which exerts a strong T cell helper function. Further, immunization
      of neonatal piglets with a P2-VP8-P[8] chimeric protein conferred significant protection
      against experimental rotavirus gastroenteritis. Based on results of the initial
      first-in-human testing of the monovalent (P[8]) vaccine, a trivalent vaccine that includes
      antigens from P[4], P[6] and P[8] strains (DS-1, 1076 and Wa, respectively) has been
      developed to broaden responses for these 3 P-types, which together are responsible for the
      vast majority of global disease burden. The trivalent vaccine was assessed in this study.

      The first clinical testing of the monovalent (P[8]) P2-VP8 subunit rotavirus vaccine was
      performed in 18-45 year old adults in North America. Overall, the vaccine was well-tolerated
      at all three dose levels, was associated with only mild transient local reactogenicity, and
      no safety concerns were identified. Almost all vaccine recipients demonstrated greater than
      4-fold rise in IgG and IgA response to P2-VP8 antigen by enzyme-linked immunosorbent assay
      (ELISA) after three vaccinations: only one vaccine recipient did not demonstrate an
      immunoglobulin G (IgG) response (in the 30 µg group) and all vaccine recipients demonstrated
      immunoglobulin A (IgA) responses. Neutralizing antibody responses were also encouraging, with
      clear increases in geometric mean titers (GMTs) for all three dose levels at one month
      post-third study injection (Day 84) compared to pre-vaccination levels. Neutralizing antibody
      responses to heterologous rotavirus strains were most robust to P[8] strains, moderate to the
      P[4] strain and fairly limited to the P[6] strain.

      Clinical testing of the monovalent (P[8]) P2-VP8 subunit rotavirus vaccine was initiated in
      South African toddlers and infants in 2014. The vaccine was generally well-tolerated at all
      three dose levels. In both toddlers and infants, when local reactogenicity was reported, it
      was transient, rarely greater than mild, and never severe. When present, systemic
      reactogenicity was also transient and generally mild, without discernable dose effect. In the
      dose-escalation phase of the testing in the infant cohorts, the study injections were paused
      temporarily due to findings of severe neutropenia on post-vaccination laboratory monitoring
      in three participants (two infants and one toddler) but were later resumed after the Safety
      Review Committee assessed that the data did not support relation to the study vaccine. The
      primary serology results in the infant cohorts were close to universal responses, with
      substantial increases in titer as demonstrated by mean-fold increase in GMT. In infants
      receiving the 30 µg dose, the GMT rose from a baseline value of 107 to a post-vaccination
      value of 9,583. Although not as dramatic as the IgG responses, there were good IgA responses
      to P2-VP8, with the seroresponse rate over 80% in infants receiving 30 µg of vaccine. The 60
      µg dose did not appear to provide any better response than the 30 µg dose, although this
      study was not powered for that comparison.

      In summary, the P2-VP8 monovalent vaccine was generally well-tolerated in healthy South
      African infants, and there was no evidence that the higher vaccine dose (60 µg) provided any
      benefit in serologic responses or impact on shedding of Rotarix compared to the lower dose
      (30 µg).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2016</start_date>
  <completion_date type="Actual">December 22, 2017</completion_date>
  <primary_completion_date type="Actual">September 1, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AE) Within 28 Days of Any Vaccination</measure>
    <time_frame>Up to 28 days after any vaccination (up to Day 28 for toddlers and up to Day 84 for infants and adults)</time_frame>
    <description>Any symptom starting after 7 days post any study injection was recorded as an adverse event. A serious adverse event (SAE) is any event that occurred from the first dose of study drug that resulted in any of the following outcomes:
Death
Life-threatening AE
Inpatient hospitalization or prolongation of existing hospitalization
Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
Congenital abnormality or birth defect
Important medical event that may not result in one of the above outcomes but may jeopardize the health of the study participant or require medical or surgical intervention to prevent one of the outcomes listed above.
The severity of adverse events was graded from Mild (grade 1) to Life Threatening (grade 4).
AEs related to study drug were those events for which there was a reasonable possibility that the study drug caused the event In the opinion of the site investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Local or Systemic Reactions Within 7 Day of Vaccination</measure>
    <time_frame>7 days following each vaccination</time_frame>
    <description>Reactogenicity data (solicited signs or symptoms) were assessed for 7 days after each injection. Participants and parents were instructed to assess and record daily local reactions (injection site pain/tenderness, redness, swelling, itching), as well as systemic signs and symptoms (fever, headache, vomiting, nausea, fatigue, chills and myalgia for adults; and fever, vomiting, decreased appetite, irritability, and decreased activity for toddlers and infants) in a participant memory aid. Reactions were graded on a scale from mild (Grade 1) to life-threatening (Grade 4).
The overall number of participants who experienced any local or systemic reaction is reported. Grades are based on maximum severity per participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Infants With Anti-P2-VP8 Immunoglobulin G (IgG) Seroresponse 4 Weeks After the Third Vaccination, by Vaccine Antigen</measure>
    <time_frame>Day 84</time_frame>
    <description>Seroresponse was defined as a four-fold rise or greater in antibody titer between Baseline and 28 days after the third injection (Day 84). Measured by enzyme-linked immunosorbent assay (ELISA) and adjusted for decay in maternal IgG antibodies. The estimated maternal antibody half-life was derived from linear regression of Log2 transformed titers in placebo recipients from the combined infant cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Infants With Anti-P2-VP8 Immunoglobulin A (IgA) Seroresponse 4 Weeks After the Third Vaccination, by Vaccine Antigen</measure>
    <time_frame>Day 84</time_frame>
    <description>Seroresponse was defined as a four-fold rise or greater in antibody titer between Baseline and 28 days after the final injection (Day 84). Measured by enzyme-linked immunosorbent assay (ELISA) to whole viral lysate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Infants With Neutralizing Antibody Responses 4 Weeks After the Third Vaccination to Each Rotavirus Strain</measure>
    <time_frame>Day 84</time_frame>
    <description>Neutralizing antibody response was defined as a ≥ 2.7-fold rise in antibody titer between Baseline and 28 days after the final injection (Day 84). Neutralizing antibodies to each of the three rotavirus strains from which the vaccine antigens were derived (Wa, DS-1, and 1076) were measured using a validated assay. For infants, antibody titer was adjusted for decay in maternal antibodies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-P2-VP8 Immunoglobulin G (IgG) Geometric Mean Titers Among Infants, by Vaccine Antigen</measure>
    <time_frame>Baseline and Days 56 (pre-vaccination) and 84</time_frame>
    <description>Measured by ELISA at Baseline, 28 days after the second injection (Day 56 pre-vaccination; secondary outcome) and 28 days after the third and final injection (Day 84; primary outcome).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-P2-VP8 Immunoglobulin A (IgA) Geometric Mean Titers Among Infants, by Vaccine Antigen</measure>
    <time_frame>Baseline and Days 56 (pre-vaccination) and 84</time_frame>
    <description>Measured by ELISA at Baseline, 28 days after the second injection (Day 56 pre-vaccination; secondary outcome) and 28 days after the third and final injection (Day 84; primary outcome).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers of Neutralizing Antibody Against Rotavirus Strains Among Infants</measure>
    <time_frame>Baseline and Days 56 (pre-vaccination) and 84</time_frame>
    <description>Neutralizing antibodies to each of the three rotavirus strains from which the vaccine antigens were derived (Wa, DS-1, and 1076) were measured at Baseline and 28 days after the second injection (Day 56 pre-vaccination; secondary outcome) and third injection (Day 84; primary outcome).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AE) Over the Entire Study Period</measure>
    <time_frame>Up to 6 months after the last injection (224 days for adults and infants; 168 days for toddlers)</time_frame>
    <description>Any symptom starting after 7 days post any study injection was recorded as an adverse event. A serious adverse event (SAE) is any event that occurred from the first dose of study drug that resulted in any of the following outcomes:
Death - Life-threatening AE
Inpatient hospitalization or prolongation of existing hospitalization
Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
Congenital abnormality or birth defect
Important medical event that may not result in one of the above outcomes but may jeopardize the health of the study participant or require medical or surgical intervention to prevent one of the outcomes listed in the above definition of serious event.
AEs related to study drug were those events for which there was a reasonable possibility that the study drug caused the event In the opinion of the site investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Anti-P2-VP8 Immunoglobulin G (IgG) Seroresponse 4 Weeks After the Second Vaccination, by Vaccine Antigen</measure>
    <time_frame>Day 56, pre-vaccination</time_frame>
    <description>Seroresponse was defined as a four-fold rise or greater in antibody titer between Baseline and 28 days after the 2nd injection (Day 56). Measured by enzyme-linked immunosorbent assay (ELISA) and adjusted for decay in maternal antibodies. The estimated maternal antibody half-life was derived from linear regression of Log2 transformed titers in placebo recipients from the combined infant cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Anti-P2-VP8 Immunoglobulin A (IgA) Seroresponse 4 Weeks After the Second Vaccination, by Vaccine Antigen</measure>
    <time_frame>Day 56, pre-vaccination</time_frame>
    <description>Seroresponse was defined as a four-fold rise or greater in antibody titer between Baseline and 28 days after the second injection (Day 56). Measured by enzyme-linked immunosorbent assay (ELISA) to whole viral lysate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Neutralizing Antibody Responses 4 Weeks After the Second Vaccination</measure>
    <time_frame>Day 56, prevaccination</time_frame>
    <description>Neutralizing antibody response was defined as a ≥ 2.7-fold rise in antibody titer between Baseline and 28 days after the second injection (Day 56). Neutralizing antibodies to each of the three rotavirus strains from which the vaccine antigens were derived (Wa, DS-1, and 1076) were measured using a validated assay. For infants, antibody titers were adjusted for decay in maternal antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adults and Toddlers With Anti-P2-VP8 Immunoglobulin G (IgG) Seroresponse, by Vaccine Antigen</measure>
    <time_frame>Day 84 for adults; Day 28 for toddlers</time_frame>
    <description>Seroresponse was defined as a four-fold rise or greater in IgG antibody titer between Baseline and 28 days after the final injection (Day 84 for adults and Day 28 for toddlers). Measured by enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adults and Toddlers With Anti-P2-VP8 Immunoglobulin A (IgA) Seroresponse, by Vaccine Antigen</measure>
    <time_frame>Day 84 for adults; Day 28 for toddlers</time_frame>
    <description>Seroresponse was defined as a four-fold rise or greater in IgA antibody titer between Baseline and 28 days after the final injection (Day 84 for adults and Day 28 for toddlers). Measured by enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adults and Toddlers With Neutralizing Antibody Responses to Each Rotavirus Strain</measure>
    <time_frame>Day 84 for adults; Day 28 for toddlers</time_frame>
    <description>Neutralizing antibody response was defined as a ≥ 2.7-fold rise in antibody titer between Baseline and 28 days after the final injection (Day 84 for adults and Day 28 for toddlers) for each of the three rotavirus strains from which the vaccine antigens were derived (Wa, DS-1, and 1076).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-P2-VP8 Immunoglobulin G (IgG) Geometric Mean Titers Among Adults and Toddlers, by Vaccine Antigen</measure>
    <time_frame>Baseline and Day 28 for toddlers or Day 84 for adults</time_frame>
    <description>Measured at Baseline and 28 days after the final injection (Day 84 for adults; Day 28 for toddlers).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-P2-VP8 Immunoglobulin A (IgA) Geometric Mean Titers Among Adults and Toddlers, by Vaccine Antigen</measure>
    <time_frame>Baseline and Day 28 for toddlers or Day 84 for adults</time_frame>
    <description>Measured at Baseline and 28 days after the final injection (Day 84 for adults; Day 28 for toddlers).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Neutralizing Antibody Against Rotavirus Strains Among Adults and Toddlers</measure>
    <time_frame>Baseline and Day 28 for toddlers or Day 84 for adults</time_frame>
    <description>Measured at Baseline and 28 days after the final injection (Day 84 for adults; Day 28 for toddlers).</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">618</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Adults: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults: 30 µg P2-VP8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults: 90 µg P2-VP8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toddlers: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Toddlers received one intramuscular injection of placebo on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toddlers: 30 µg P2-VP8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toddlers: 90 µg P2-VP8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants: 15 µg P2-VP8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants: 30 µg P2-VP8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants: 90 µg P2-VP8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent P2-VP8 Subunit Rotavirus Vaccine</intervention_name>
    <description>Manufactured and supplied by the Walter Reed Army Institute of Research (WRAIR) Pilot Bioproduction Facility (BPF). The trivalent P2-VP8 vaccine was formulated as a sterile suspension containing a total of 360 µg of protein (120 µg of each P type) per mL adsorbed to aluminum hydroxide (1.125 mg of aluminum per mL in a phosphate buffer, pH 7).</description>
    <arm_group_label>Adults: 30 µg P2-VP8</arm_group_label>
    <arm_group_label>Adults: 90 µg P2-VP8</arm_group_label>
    <arm_group_label>Infants: 15 µg P2-VP8</arm_group_label>
    <arm_group_label>Infants: 30 µg P2-VP8</arm_group_label>
    <arm_group_label>Infants: 90 µg P2-VP8</arm_group_label>
    <arm_group_label>Toddlers: 30 µg P2-VP8</arm_group_label>
    <arm_group_label>Toddlers: 90 µg P2-VP8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sodium Chloride 0.9%, USP for Injection</description>
    <arm_group_label>Adults: Placebo</arm_group_label>
    <arm_group_label>Infants: Placebo</arm_group_label>
    <arm_group_label>Toddlers: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults (≥ 18 and ≤ 45 years), toddlers (≥ 2 and ≤ 3 years), and infants (≥ 6
             and ≤ 8 weeks)

          -  Participants will remain in the area during the study

          -  Females of childbearing potential must not be pregnant or breastfeeding, and willing
             to use adequate method of contraception during the trial.

        Exclusion Criteria:

          -  Presence of fever or other acute illness

          -  concurrent participation in another clinical trial

          -  Presence of malnutrition or other systemic disorder.

          -  Infants with history of premature birth (&lt; 37 week gestational age)

          -  History of congenital abdominal disorders or surgery

          -  Suspected or known impairment of immune function

          -  Infants who have received rotavirus vaccine in the past

          -  Known sensitivity to any components of the vaccine

          -  History of anaphylactic reaction

          -  Major congenital or genetic defect

          -  Unwillingness to follow study schedule

          -  Receipt of immunoglobulin therapy or blood products in last 6 months

          -  History of chronic immunosuppressive medications (with the exception of inhaled or
             topical steroids)

          -  Any medical condition that, in the judgement of the investigator, would interfere with
             the protocol, or would interfere with participant's ability to adhere to the study
             protocol.

          -  Clinically significant screening laboratory value

          -  Human immunodeficiency virus (HIV) infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Groom, MBBCh</last_name>
    <role>Study Chair</role>
    <affiliation>Chris Hani Baragwanath Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Respiratory and Meningeal Pathogens Research Unit (RMPRU)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandukani Research Centre</name>
      <address>
        <city>Johannesburg</city>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Clinical Research Unit (FAM-CRU) Stellenbosch Univ</name>
      <address>
        <city>Stellenbosch</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <results_first_submitted>January 2, 2019</results_first_submitted>
  <results_first_submitted_qc>February 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2020</results_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rotavirus Vaccine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT02646891/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT02646891/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Adult: Placebo</title>
          <description>Adult participants who received three intramuscular injections of placebo four weeks apart on days 0, 28, and 56. Approximately half of the participants were compared to the arm receiving the 30 µg dose of P2-VP8; once the safety of this dose was established, the other half were compared to the arm receiving 90 µg.</description>
        </group>
        <group group_id="P2">
          <title>Adult: P2-VP8 (30 µg)</title>
          <description>Adult participants who received three intramuscular injections of Trivalent P2-VP8 Subunit Rotavirus Vaccine (30 µg) four weeks apart on days 0, 28, and 56.</description>
        </group>
        <group group_id="P3">
          <title>Adult: P2-VP8 (90 µg)</title>
          <description>Adult participants who received three intramuscular injections of Trivalent P2-VP8 Subunit Rotavirus Vaccine (90 µg) four weeks apart on days 0, 28, and 56.</description>
        </group>
        <group group_id="P4">
          <title>Toddler: Placebo</title>
          <description>Toddler participants who received one intramuscular injection of placebo on day 0. Approximately half of the participants were compared to the arm receiving the 30 µg dose of P2-VP8; once the safety of this dose was established, the other half were compared to the arm receiving 90 µg.</description>
        </group>
        <group group_id="P5">
          <title>Toddler: P2-VP8 (30 µg)</title>
          <description>Toddler participants who received one intramuscular injections of Trivalent P2-VP8 Subunit Rotavirus Vaccine (30 µg) on day 0.</description>
        </group>
        <group group_id="P6">
          <title>Toddler: P2-VP8 (90 µg)</title>
          <description>Toddler participants who received one intramuscular injection of Trivalent P2-VP8 Subunit Rotavirus Vaccine (90 µg) on day 0.</description>
        </group>
        <group group_id="P7">
          <title>Infant: Placebo</title>
          <description>Infant participants who received three intramuscular injections of placebo four weeks apart on days 0, 28, and 56. Approximately one third of the participants were compared to the arm receiving the 15 µg dose of P2-VP8; once the safety of the 15 µg dose was established, one third of the participants were compared to the arm receiving 30 µg; and the last third were compared to the arm receiving 90 µg after the safety of the 30 µg dose was established.</description>
        </group>
        <group group_id="P8">
          <title>Infant: P2-VP8 (15 µg)</title>
          <description>Infant participants who received three intramuscular injections of Trivalent P2-VP8 Subunit Rotavirus Vaccine (15 µg) four weeks apart on days 0, 28, and 56.</description>
        </group>
        <group group_id="P9">
          <title>Infant: P2-VP8 (30 µg)</title>
          <description>Infant participants who received three intramuscular injections of Trivalent P2-VP8 Subunit Rotavirus Vaccine (30 µg) four weeks apart on days 0, 28, and 56.</description>
        </group>
        <group group_id="P10">
          <title>Infant: P2-VP8 (90 µg)</title>
          <description>Infant participants who received three intramuscular injections of Trivalent P2-VP8 Subunit Rotavirus Vaccine (90 µg) four weeks apart on days 0, 28, and 56.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="139"/>
                <participants group_id="P8" count="140"/>
                <participants group_id="P9" count="140"/>
                <participants group_id="P10" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="139"/>
                <participants group_id="P8" count="139">One participant was randomized but determined to be ineligible pre-vaccination.</participants>
                <participants group_id="P9" count="140"/>
                <participants group_id="P10" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="130"/>
                <participants group_id="P8" count="127"/>
                <participants group_id="P9" count="130"/>
                <participants group_id="P10" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="13"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adults: Placebo</title>
          <description>Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
        </group>
        <group group_id="B2">
          <title>Adults: 30 µg P2-VP8</title>
          <description>Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
        </group>
        <group group_id="B3">
          <title>Adults: 90 µg P2-VP8</title>
          <description>Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
        </group>
        <group group_id="B4">
          <title>Toddlers: Placebo</title>
          <description>Toddlers received one intramuscular injection of placebo on Day 0.</description>
        </group>
        <group group_id="B5">
          <title>Toddlers: 30 µg P2-VP8</title>
          <description>Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
        </group>
        <group group_id="B6">
          <title>Toddlers: 90 µg P2-VP8</title>
          <description>Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
        </group>
        <group group_id="B7">
          <title>Infants: Placebo</title>
          <description>Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
        </group>
        <group group_id="B8">
          <title>Infants: 15 µg P2-VP8</title>
          <description>Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
        </group>
        <group group_id="B9">
          <title>Infants: 30 µg P2-VP8</title>
          <description>Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
        </group>
        <group group_id="B10">
          <title>Infants: 90 µg P2-VP8</title>
          <description>Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="139"/>
            <count group_id="B8" value="140"/>
            <count group_id="B9" value="140"/>
            <count group_id="B10" value="139"/>
            <count group_id="B11" value="618"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="12"/>
                    <count group_id="B7" value="139"/>
                    <count group_id="B8" value="140"/>
                    <count group_id="B9" value="140"/>
                    <count group_id="B10" value="139"/>
                    <count group_id="B11" value="618"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.3" spread="2.1"/>
                    <measurement group_id="B2" value="32.0" spread="4.8"/>
                    <measurement group_id="B3" value="26.0" spread="6.0"/>
                    <measurement group_id="B4" value="2.6" spread="0.1"/>
                    <measurement group_id="B5" value="2.6" spread="0.2"/>
                    <measurement group_id="B6" value="2.5" spread="0.2"/>
                    <measurement group_id="B7" value="0.13" spread="0.01"/>
                    <measurement group_id="B8" value="0.13" spread="0.01"/>
                    <measurement group_id="B9" value="0.13" spread="0.01"/>
                    <measurement group_id="B10" value="0.13" spread="0.01"/>
                    <measurement group_id="B11" value="16.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="12"/>
                    <count group_id="B7" value="139"/>
                    <count group_id="B8" value="140"/>
                    <count group_id="B9" value="140"/>
                    <count group_id="B10" value="139"/>
                    <count group_id="B11" value="618"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="67"/>
                    <measurement group_id="B8" value="66"/>
                    <measurement group_id="B9" value="76"/>
                    <measurement group_id="B10" value="64"/>
                    <measurement group_id="B11" value="307"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="72"/>
                    <measurement group_id="B8" value="74"/>
                    <measurement group_id="B9" value="64"/>
                    <measurement group_id="B10" value="75"/>
                    <measurement group_id="B11" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="12"/>
                    <count group_id="B7" value="139"/>
                    <count group_id="B8" value="140"/>
                    <count group_id="B9" value="140"/>
                    <count group_id="B10" value="139"/>
                    <count group_id="B11" value="618"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="137"/>
                    <measurement group_id="B8" value="138"/>
                    <measurement group_id="B9" value="138"/>
                    <measurement group_id="B10" value="136"/>
                    <measurement group_id="B11" value="609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="12"/>
                    <count group_id="B7" value="139"/>
                    <count group_id="B8" value="140"/>
                    <count group_id="B9" value="140"/>
                    <count group_id="B10" value="139"/>
                    <count group_id="B11" value="618"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="12"/>
                    <count group_id="B7" value="139"/>
                    <count group_id="B8" value="140"/>
                    <count group_id="B9" value="140"/>
                    <count group_id="B10" value="139"/>
                    <count group_id="B11" value="618"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colored</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="12"/>
                    <count group_id="B7" value="139"/>
                    <count group_id="B8" value="140"/>
                    <count group_id="B9" value="140"/>
                    <count group_id="B10" value="139"/>
                    <count group_id="B11" value="618"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unspecified</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="12"/>
                    <count group_id="B7" value="139"/>
                    <count group_id="B8" value="140"/>
                    <count group_id="B9" value="140"/>
                    <count group_id="B10" value="139"/>
                    <count group_id="B11" value="618"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Height was not collected for one participant.</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="12"/>
                    <count group_id="B7" value="138"/>
                    <count group_id="B8" value="140"/>
                    <count group_id="B9" value="140"/>
                    <count group_id="B10" value="139"/>
                    <count group_id="B11" value="617"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167.0" spread="12.5"/>
                    <measurement group_id="B2" value="164.4" spread="10.6"/>
                    <measurement group_id="B3" value="160.6" spread="8.3"/>
                    <measurement group_id="B4" value="88.8" spread="6.8"/>
                    <measurement group_id="B5" value="86.4" spread="7.6"/>
                    <measurement group_id="B6" value="88.5" spread="4.3"/>
                    <measurement group_id="B7" value="55.4" spread="2.35"/>
                    <measurement group_id="B8" value="54.9" spread="2.48"/>
                    <measurement group_id="B9" value="55.1" spread="2.24"/>
                    <measurement group_id="B10" value="55.3" spread="1.98"/>
                    <measurement group_id="B11" value="62.0" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Weight for one participant was missing.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="11"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="12"/>
                    <count group_id="B7" value="139"/>
                    <count group_id="B8" value="140"/>
                    <count group_id="B9" value="140"/>
                    <count group_id="B10" value="139"/>
                    <count group_id="B11" value="617"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.7" spread="8.1"/>
                    <measurement group_id="B2" value="68.7" spread="10.4"/>
                    <measurement group_id="B3" value="61.2" spread="10.2"/>
                    <measurement group_id="B4" value="13.8" spread="2.4"/>
                    <measurement group_id="B5" value="12.6" spread="1.5"/>
                    <measurement group_id="B6" value="13.5" spread="2.3"/>
                    <measurement group_id="B7" value="4.9" spread="0.59"/>
                    <measurement group_id="B8" value="4.8" spread="0.66"/>
                    <measurement group_id="B9" value="4.8" spread="0.54"/>
                    <measurement group_id="B10" value="4.9" spread="0.58"/>
                    <measurement group_id="B11" value="8.1" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Adverse Events (AE) Within 28 Days of Any Vaccination</title>
        <description>Any symptom starting after 7 days post any study injection was recorded as an adverse event. A serious adverse event (SAE) is any event that occurred from the first dose of study drug that resulted in any of the following outcomes:
Death
Life-threatening AE
Inpatient hospitalization or prolongation of existing hospitalization
Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
Congenital abnormality or birth defect
Important medical event that may not result in one of the above outcomes but may jeopardize the health of the study participant or require medical or surgical intervention to prevent one of the outcomes listed above.
The severity of adverse events was graded from Mild (grade 1) to Life Threatening (grade 4).
AEs related to study drug were those events for which there was a reasonable possibility that the study drug caused the event In the opinion of the site investigator.</description>
        <time_frame>Up to 28 days after any vaccination (up to Day 28 for toddlers and up to Day 84 for infants and adults)</time_frame>
        <population>Safety population included all participants who were randomized and received at least one injection of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults: Placebo</title>
            <description>Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Adults: 30 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Adults: 90 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Toddlers: Placebo</title>
            <description>Toddlers received one intramuscular injection of placebo on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Toddlers: 30 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>Toddlers: 90 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
          <group group_id="O7">
            <title>Infants: Placebo</title>
            <description>Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O8">
            <title>Infants: 15 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O9">
            <title>Infants: 30 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O10">
            <title>Infants: 90 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events (AE) Within 28 Days of Any Vaccination</title>
          <description>Any symptom starting after 7 days post any study injection was recorded as an adverse event. A serious adverse event (SAE) is any event that occurred from the first dose of study drug that resulted in any of the following outcomes:
Death
Life-threatening AE
Inpatient hospitalization or prolongation of existing hospitalization
Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
Congenital abnormality or birth defect
Important medical event that may not result in one of the above outcomes but may jeopardize the health of the study participant or require medical or surgical intervention to prevent one of the outcomes listed above.
The severity of adverse events was graded from Mild (grade 1) to Life Threatening (grade 4).
AEs related to study drug were those events for which there was a reasonable possibility that the study drug caused the event In the opinion of the site investigator.</description>
          <population>Safety population included all participants who were randomized and received at least one injection of the study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="139"/>
                <count group_id="O8" value="139"/>
                <count group_id="O9" value="140"/>
                <count group_id="O10" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="119"/>
                    <measurement group_id="O8" value="118"/>
                    <measurement group_id="O9" value="122"/>
                    <measurement group_id="O10" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any grade 2 or higher AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="19"/>
                    <measurement group_id="O8" value="24"/>
                    <measurement group_id="O9" value="18"/>
                    <measurement group_id="O10" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any grade 2 or higher AE related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Local or Systemic Reactions Within 7 Day of Vaccination</title>
        <description>Reactogenicity data (solicited signs or symptoms) were assessed for 7 days after each injection. Participants and parents were instructed to assess and record daily local reactions (injection site pain/tenderness, redness, swelling, itching), as well as systemic signs and symptoms (fever, headache, vomiting, nausea, fatigue, chills and myalgia for adults; and fever, vomiting, decreased appetite, irritability, and decreased activity for toddlers and infants) in a participant memory aid. Reactions were graded on a scale from mild (Grade 1) to life-threatening (Grade 4).
The overall number of participants who experienced any local or systemic reaction is reported. Grades are based on maximum severity per participant.</description>
        <time_frame>7 days following each vaccination</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Adults: Placebo</title>
            <description>Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Adults: 30 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Adults: 90 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Toddlers: Placebo</title>
            <description>Toddlers received one intramuscular injection of placebo on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Toddlers: 30 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>Toddlers: 90 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
          <group group_id="O7">
            <title>Infants: Placebo</title>
            <description>Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O8">
            <title>Infants: 15 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O9">
            <title>Infants: 30 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O10">
            <title>Infants: 90 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local or Systemic Reactions Within 7 Day of Vaccination</title>
          <description>Reactogenicity data (solicited signs or symptoms) were assessed for 7 days after each injection. Participants and parents were instructed to assess and record daily local reactions (injection site pain/tenderness, redness, swelling, itching), as well as systemic signs and symptoms (fever, headache, vomiting, nausea, fatigue, chills and myalgia for adults; and fever, vomiting, decreased appetite, irritability, and decreased activity for toddlers and infants) in a participant memory aid. Reactions were graded on a scale from mild (Grade 1) to life-threatening (Grade 4).
The overall number of participants who experienced any local or systemic reaction is reported. Grades are based on maximum severity per participant.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="139"/>
                <count group_id="O8" value="139"/>
                <count group_id="O9" value="140"/>
                <count group_id="O10" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="93"/>
                    <measurement group_id="O8" value="102"/>
                    <measurement group_id="O9" value="109"/>
                    <measurement group_id="O10" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reaction: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="84"/>
                    <measurement group_id="O8" value="83"/>
                    <measurement group_id="O9" value="96"/>
                    <measurement group_id="O10" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reaction: Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="19"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reaction: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reaction: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="116"/>
                    <measurement group_id="O8" value="114"/>
                    <measurement group_id="O9" value="113"/>
                    <measurement group_id="O10" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction: Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="86"/>
                    <measurement group_id="O8" value="70"/>
                    <measurement group_id="O9" value="83"/>
                    <measurement group_id="O10" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction : Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="39"/>
                    <measurement group_id="O9" value="28"/>
                    <measurement group_id="O10" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction: Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction: Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Infants With Anti-P2-VP8 Immunoglobulin G (IgG) Seroresponse 4 Weeks After the Third Vaccination, by Vaccine Antigen</title>
        <description>Seroresponse was defined as a four-fold rise or greater in antibody titer between Baseline and 28 days after the third injection (Day 84). Measured by enzyme-linked immunosorbent assay (ELISA) and adjusted for decay in maternal IgG antibodies. The estimated maternal antibody half-life was derived from linear regression of Log2 transformed titers in placebo recipients from the combined infant cohorts.</description>
        <time_frame>Day 84</time_frame>
        <population>Per-protocol population included all randomized participants who adhered to the protocol, completed all their scheduled visits and vaccinations up to the analysis time point and presented no major protocol violations (defined as a protocol violation that was considered to have an impact on the immunogenicity results of the study).</population>
        <group_list>
          <group group_id="O1">
            <title>Infants: Placebo</title>
            <description>Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Infants: 15 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Infants: 30 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Infants: 90 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Anti-P2-VP8 Immunoglobulin G (IgG) Seroresponse 4 Weeks After the Third Vaccination, by Vaccine Antigen</title>
          <description>Seroresponse was defined as a four-fold rise or greater in antibody titer between Baseline and 28 days after the third injection (Day 84). Measured by enzyme-linked immunosorbent assay (ELISA) and adjusted for decay in maternal IgG antibodies. The estimated maternal antibody half-life was derived from linear regression of Log2 transformed titers in placebo recipients from the combined infant cohorts.</description>
          <population>Per-protocol population included all randomized participants who adhered to the protocol, completed all their scheduled visits and vaccinations up to the analysis time point and presented no major protocol violations (defined as a protocol violation that was considered to have an impact on the immunogenicity results of the study).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P[4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="131"/>
                    <measurement group_id="O3" value="130"/>
                    <measurement group_id="O4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="131"/>
                    <measurement group_id="O3" value="132"/>
                    <measurement group_id="O4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="131"/>
                    <measurement group_id="O3" value="130"/>
                    <measurement group_id="O4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any 2 antigens</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="131"/>
                    <measurement group_id="O3" value="130"/>
                    <measurement group_id="O4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All 3 antigens</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="131"/>
                    <measurement group_id="O3" value="130"/>
                    <measurement group_id="O4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Infants With Anti-P2-VP8 Immunoglobulin A (IgA) Seroresponse 4 Weeks After the Third Vaccination, by Vaccine Antigen</title>
        <description>Seroresponse was defined as a four-fold rise or greater in antibody titer between Baseline and 28 days after the final injection (Day 84). Measured by enzyme-linked immunosorbent assay (ELISA) to whole viral lysate.</description>
        <time_frame>Day 84</time_frame>
        <population>Per-protocol population participants with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Infants: Placebo</title>
            <description>Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Infants: 15 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Infants: 30 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Infants: 90 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Anti-P2-VP8 Immunoglobulin A (IgA) Seroresponse 4 Weeks After the Third Vaccination, by Vaccine Antigen</title>
          <description>Seroresponse was defined as a four-fold rise or greater in antibody titer between Baseline and 28 days after the final injection (Day 84). Measured by enzyme-linked immunosorbent assay (ELISA) to whole viral lysate.</description>
          <population>Per-protocol population participants with available data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P[4]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[6]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[8]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any 2 antigens</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All 3 antigens</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Infants With Neutralizing Antibody Responses 4 Weeks After the Third Vaccination to Each Rotavirus Strain</title>
        <description>Neutralizing antibody response was defined as a ≥ 2.7-fold rise in antibody titer between Baseline and 28 days after the final injection (Day 84). Neutralizing antibodies to each of the three rotavirus strains from which the vaccine antigens were derived (Wa, DS-1, and 1076) were measured using a validated assay. For infants, antibody titer was adjusted for decay in maternal antibodies.</description>
        <time_frame>Day 84</time_frame>
        <population>Per-protocol population participants with available data for each strain</population>
        <group_list>
          <group group_id="O1">
            <title>Infants: Placebo</title>
            <description>Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Infants: 15 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Infants: 30 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Infants: 90 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Neutralizing Antibody Responses 4 Weeks After the Third Vaccination to Each Rotavirus Strain</title>
          <description>Neutralizing antibody response was defined as a ≥ 2.7-fold rise in antibody titer between Baseline and 28 days after the final injection (Day 84). Neutralizing antibodies to each of the three rotavirus strains from which the vaccine antigens were derived (Wa, DS-1, and 1076) were measured using a validated assay. For infants, antibody titer was adjusted for decay in maternal antibodies.</description>
          <population>Per-protocol population participants with available data for each strain</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rotavirus strain Wa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="107"/>
                    <measurement group_id="O4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rotavirus strain DS-1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rotavirus strain 1076</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="103"/>
                    <measurement group_id="O4" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any 2 strains</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="108"/>
                    <measurement group_id="O4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All 3 strains</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-P2-VP8 Immunoglobulin G (IgG) Geometric Mean Titers Among Infants, by Vaccine Antigen</title>
        <description>Measured by ELISA at Baseline, 28 days after the second injection (Day 56 pre-vaccination; secondary outcome) and 28 days after the third and final injection (Day 84; primary outcome).</description>
        <time_frame>Baseline and Days 56 (pre-vaccination) and 84</time_frame>
        <population>Per-protocol population; participants with valid specimens at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Infants: Placebo</title>
            <description>Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Infants: 15 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Infants: 30 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Infants: 90 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-P2-VP8 Immunoglobulin G (IgG) Geometric Mean Titers Among Infants, by Vaccine Antigen</title>
          <description>Measured by ELISA at Baseline, 28 days after the second injection (Day 56 pre-vaccination; secondary outcome) and 28 days after the third and final injection (Day 84; primary outcome).</description>
          <population>Per-protocol population; participants with valid specimens at each time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P[4]: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="57" upper_limit="94"/>
                    <measurement group_id="O2" value="80" lower_limit="64" upper_limit="101"/>
                    <measurement group_id="O3" value="62" lower_limit="48" upper_limit="79"/>
                    <measurement group_id="O4" value="76" lower_limit="62" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[4]: Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="24" upper_limit="38"/>
                    <measurement group_id="O2" value="1456" lower_limit="1244" upper_limit="1705"/>
                    <measurement group_id="O3" value="1849" lower_limit="1581" upper_limit="2163"/>
                    <measurement group_id="O4" value="2424" lower_limit="2099" upper_limit="2800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[4]: Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="22" upper_limit="36"/>
                    <measurement group_id="O2" value="3888" lower_limit="3313" upper_limit="4562"/>
                    <measurement group_id="O3" value="4205" lower_limit="3692" upper_limit="4789"/>
                    <measurement group_id="O4" value="5244" lower_limit="4729" upper_limit="5815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[6]: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="52" upper_limit="86"/>
                    <measurement group_id="O2" value="73" lower_limit="58" upper_limit="92"/>
                    <measurement group_id="O3" value="63" lower_limit="49" upper_limit="82"/>
                    <measurement group_id="O4" value="66" lower_limit="52" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[6]: Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="38" upper_limit="58"/>
                    <measurement group_id="O2" value="5031" lower_limit="4305" upper_limit="5880"/>
                    <measurement group_id="O3" value="5709" lower_limit="4932" upper_limit="6609"/>
                    <measurement group_id="O4" value="7122" lower_limit="6176" upper_limit="8213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[6]: Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="39" upper_limit="64"/>
                    <measurement group_id="O2" value="14028" lower_limit="11980" upper_limit="16426"/>
                    <measurement group_id="O3" value="14724" lower_limit="13181" upper_limit="16447"/>
                    <measurement group_id="O4" value="17085" lower_limit="15295" upper_limit="19085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[8]: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="66" upper_limit="109"/>
                    <measurement group_id="O2" value="86" lower_limit="69" upper_limit="109"/>
                    <measurement group_id="O3" value="74" lower_limit="59" upper_limit="94"/>
                    <measurement group_id="O4" value="81" lower_limit="65" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[8]: Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="28" upper_limit="45"/>
                    <measurement group_id="O2" value="1897" lower_limit="1616" upper_limit="2227"/>
                    <measurement group_id="O3" value="2323" lower_limit="1985" upper_limit="2719"/>
                    <measurement group_id="O4" value="3050" lower_limit="2621" upper_limit="3549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[8]: Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="23" upper_limit="39"/>
                    <measurement group_id="O2" value="5365" lower_limit="4454" upper_limit="6321"/>
                    <measurement group_id="O3" value="5792" lower_limit="5086" upper_limit="6595"/>
                    <measurement group_id="O4" value="7088" lower_limit="6314" upper_limit="7958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-P2-VP8 Immunoglobulin A (IgA) Geometric Mean Titers Among Infants, by Vaccine Antigen</title>
        <description>Measured by ELISA at Baseline, 28 days after the second injection (Day 56 pre-vaccination; secondary outcome) and 28 days after the third and final injection (Day 84; primary outcome).</description>
        <time_frame>Baseline and Days 56 (pre-vaccination) and 84</time_frame>
        <population>Per-protocol population; participants with valid specimens at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Infants: Placebo</title>
            <description>Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Infants: 15 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Infants: 30 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Infants: 90 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-P2-VP8 Immunoglobulin A (IgA) Geometric Mean Titers Among Infants, by Vaccine Antigen</title>
          <description>Measured by ELISA at Baseline, 28 days after the second injection (Day 56 pre-vaccination; secondary outcome) and 28 days after the third and final injection (Day 84; primary outcome).</description>
          <population>Per-protocol population; participants with valid specimens at each time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P[4]: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="6"/>
                    <measurement group_id="O3" value="5" lower_limit="5" upper_limit="5"/>
                    <measurement group_id="O4" value="5" lower_limit="5" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[4]: Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="7"/>
                    <measurement group_id="O2" value="9" lower_limit="7" upper_limit="11"/>
                    <measurement group_id="O3" value="10" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="O4" value="9" lower_limit="7" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[4]: Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="O2" value="13" lower_limit="10" upper_limit="17"/>
                    <measurement group_id="O3" value="12" lower_limit="10" upper_limit="15"/>
                    <measurement group_id="O4" value="10" lower_limit="9" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[6]: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="5"/>
                    <measurement group_id="O2" value="5" lower_limit="5" upper_limit="6"/>
                    <measurement group_id="O3" value="5" lower_limit="4" upper_limit="5"/>
                    <measurement group_id="O4" value="5" lower_limit="5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[6]: Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="6" upper_limit="7"/>
                    <measurement group_id="O2" value="9" lower_limit="7" upper_limit="10"/>
                    <measurement group_id="O3" value="10" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="O4" value="10" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[6]: Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="6" upper_limit="8"/>
                    <measurement group_id="O2" value="12" lower_limit="10" upper_limit="15"/>
                    <measurement group_id="O3" value="13" lower_limit="10" upper_limit="15"/>
                    <measurement group_id="O4" value="12" lower_limit="10" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[8]: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="5"/>
                    <measurement group_id="O2" value="5" lower_limit="4" upper_limit="5"/>
                    <measurement group_id="O3" value="5" lower_limit="4" upper_limit="5"/>
                    <measurement group_id="O4" value="5" lower_limit="5" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[8]: Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="6"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="9"/>
                    <measurement group_id="O3" value="8" lower_limit="7" upper_limit="9"/>
                    <measurement group_id="O4" value="7" lower_limit="6" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[8]: Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="7"/>
                    <measurement group_id="O2" value="11" lower_limit="9" upper_limit="13"/>
                    <measurement group_id="O3" value="9" lower_limit="8" upper_limit="11"/>
                    <measurement group_id="O4" value="8" lower_limit="7" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers of Neutralizing Antibody Against Rotavirus Strains Among Infants</title>
        <description>Neutralizing antibodies to each of the three rotavirus strains from which the vaccine antigens were derived (Wa, DS-1, and 1076) were measured at Baseline and 28 days after the second injection (Day 56 pre-vaccination; secondary outcome) and third injection (Day 84; primary outcome).</description>
        <time_frame>Baseline and Days 56 (pre-vaccination) and 84</time_frame>
        <population>Per-protocol population participants with valid specimens at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Infants: Placebo</title>
            <description>Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Infants: 15 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Infants: 30 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Infants: 90 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Neutralizing Antibody Against Rotavirus Strains Among Infants</title>
          <description>Neutralizing antibodies to each of the three rotavirus strains from which the vaccine antigens were derived (Wa, DS-1, and 1076) were measured at Baseline and 28 days after the second injection (Day 56 pre-vaccination; secondary outcome) and third injection (Day 84; primary outcome).</description>
          <population>Per-protocol population participants with valid specimens at each time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain Wa: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118" lower_limit="99" upper_limit="142"/>
                    <measurement group_id="O2" value="154" lower_limit="131" upper_limit="181"/>
                    <measurement group_id="O3" value="128" lower_limit="108" upper_limit="152"/>
                    <measurement group_id="O4" value="130" lower_limit="110" upper_limit="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain Wa: Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="34" upper_limit="52"/>
                    <measurement group_id="O2" value="90" lower_limit="77" upper_limit="104"/>
                    <measurement group_id="O3" value="85" lower_limit="74" upper_limit="97"/>
                    <measurement group_id="O4" value="85" lower_limit="75" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain Wa: Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="34" upper_limit="52"/>
                    <measurement group_id="O2" value="90" lower_limit="77" upper_limit="104"/>
                    <measurement group_id="O3" value="85" lower_limit="74" upper_limit="97"/>
                    <measurement group_id="O4" value="85" lower_limit="75" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain DS-1: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="45" upper_limit="64"/>
                    <measurement group_id="O2" value="51" lower_limit="41" upper_limit="62"/>
                    <measurement group_id="O3" value="44" lower_limit="36" upper_limit="54"/>
                    <measurement group_id="O4" value="46" lower_limit="38" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain DS-1: Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="13" upper_limit="19"/>
                    <measurement group_id="O2" value="26" lower_limit="22" upper_limit="30"/>
                    <measurement group_id="O3" value="26" lower_limit="22" upper_limit="31"/>
                    <measurement group_id="O4" value="27" lower_limit="23" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain DS-1: Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="131"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9" upper_limit="13"/>
                    <measurement group_id="O2" value="49" lower_limit="42" upper_limit="58"/>
                    <measurement group_id="O3" value="48" lower_limit="42" upper_limit="55"/>
                    <measurement group_id="O4" value="53" lower_limit="46" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain 1076: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="25" upper_limit="38"/>
                    <measurement group_id="O2" value="37" lower_limit="31" upper_limit="44"/>
                    <measurement group_id="O3" value="30" lower_limit="25" upper_limit="36"/>
                    <measurement group_id="O4" value="35" lower_limit="29" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain 1076: Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="10" upper_limit="15"/>
                    <measurement group_id="O2" value="18" lower_limit="16" upper_limit="22"/>
                    <measurement group_id="O3" value="18" lower_limit="15" upper_limit="21"/>
                    <measurement group_id="O4" value="20" lower_limit="17" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain 1076: Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="132"/>
                    <count group_id="O4" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8" upper_limit="11"/>
                    <measurement group_id="O2" value="34" lower_limit="29" upper_limit="40"/>
                    <measurement group_id="O3" value="35" lower_limit="30" upper_limit="40"/>
                    <measurement group_id="O4" value="43" lower_limit="38" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Adverse Events (AE) Over the Entire Study Period</title>
        <description>Any symptom starting after 7 days post any study injection was recorded as an adverse event. A serious adverse event (SAE) is any event that occurred from the first dose of study drug that resulted in any of the following outcomes:
Death - Life-threatening AE
Inpatient hospitalization or prolongation of existing hospitalization
Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
Congenital abnormality or birth defect
Important medical event that may not result in one of the above outcomes but may jeopardize the health of the study participant or require medical or surgical intervention to prevent one of the outcomes listed in the above definition of serious event.
AEs related to study drug were those events for which there was a reasonable possibility that the study drug caused the event In the opinion of the site investigator.</description>
        <time_frame>Up to 6 months after the last injection (224 days for adults and infants; 168 days for toddlers)</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Adults: Placebo</title>
            <description>Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Adults: 30 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Adults: 90 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Toddlers: Placebo</title>
            <description>Toddlers received one intramuscular injection of placebo on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Toddlers: 30 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>Toddlers: 90 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
          <group group_id="O7">
            <title>Infants: Placebo</title>
            <description>Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O8">
            <title>Infants: 15 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O9">
            <title>Infants: 30 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O10">
            <title>Infants: 90 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events (AE) Over the Entire Study Period</title>
          <description>Any symptom starting after 7 days post any study injection was recorded as an adverse event. A serious adverse event (SAE) is any event that occurred from the first dose of study drug that resulted in any of the following outcomes:
Death - Life-threatening AE
Inpatient hospitalization or prolongation of existing hospitalization
Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
Congenital abnormality or birth defect
Important medical event that may not result in one of the above outcomes but may jeopardize the health of the study participant or require medical or surgical intervention to prevent one of the outcomes listed in the above definition of serious event.
AEs related to study drug were those events for which there was a reasonable possibility that the study drug caused the event In the opinion of the site investigator.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="139"/>
                <count group_id="O8" value="139"/>
                <count group_id="O9" value="140"/>
                <count group_id="O10" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="132"/>
                    <measurement group_id="O8" value="129"/>
                    <measurement group_id="O9" value="134"/>
                    <measurement group_id="O10" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any grade 2 or higher AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="27"/>
                    <measurement group_id="O8" value="43"/>
                    <measurement group_id="O9" value="28"/>
                    <measurement group_id="O10" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any grade 2 or higher AE related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Anti-P2-VP8 Immunoglobulin G (IgG) Seroresponse 4 Weeks After the Second Vaccination, by Vaccine Antigen</title>
        <description>Seroresponse was defined as a four-fold rise or greater in antibody titer between Baseline and 28 days after the 2nd injection (Day 56). Measured by enzyme-linked immunosorbent assay (ELISA) and adjusted for decay in maternal antibodies. The estimated maternal antibody half-life was derived from linear regression of Log2 transformed titers in placebo recipients from the combined infant cohorts.</description>
        <time_frame>Day 56, pre-vaccination</time_frame>
        <population>Per-protocol population; participants with available data for each antigen</population>
        <group_list>
          <group group_id="O1">
            <title>Infants: Placebo</title>
            <description>Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Infants: 15 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Infants: 30 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Infants: 90 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Anti-P2-VP8 Immunoglobulin G (IgG) Seroresponse 4 Weeks After the Second Vaccination, by Vaccine Antigen</title>
          <description>Seroresponse was defined as a four-fold rise or greater in antibody titer between Baseline and 28 days after the 2nd injection (Day 56). Measured by enzyme-linked immunosorbent assay (ELISA) and adjusted for decay in maternal antibodies. The estimated maternal antibody half-life was derived from linear regression of Log2 transformed titers in placebo recipients from the combined infant cohorts.</description>
          <population>Per-protocol population; participants with available data for each antigen</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P[4]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="121"/>
                    <measurement group_id="O4" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[6]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[8]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="119"/>
                    <measurement group_id="O4" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any 2 antigens</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="121"/>
                    <measurement group_id="O4" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All 3 antigens</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="114"/>
                    <measurement group_id="O4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Anti-P2-VP8 Immunoglobulin A (IgA) Seroresponse 4 Weeks After the Second Vaccination, by Vaccine Antigen</title>
        <description>Seroresponse was defined as a four-fold rise or greater in antibody titer between Baseline and 28 days after the second injection (Day 56). Measured by enzyme-linked immunosorbent assay (ELISA) to whole viral lysate.</description>
        <time_frame>Day 56, pre-vaccination</time_frame>
        <population>Per-protocol population; participants with available data for each antigen</population>
        <group_list>
          <group group_id="O1">
            <title>Infants: Placebo</title>
            <description>Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Infants: 15 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Infants: 30 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Infants: 90 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Anti-P2-VP8 Immunoglobulin A (IgA) Seroresponse 4 Weeks After the Second Vaccination, by Vaccine Antigen</title>
          <description>Seroresponse was defined as a four-fold rise or greater in antibody titer between Baseline and 28 days after the second injection (Day 56). Measured by enzyme-linked immunosorbent assay (ELISA) to whole viral lysate.</description>
          <population>Per-protocol population; participants with available data for each antigen</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P[4]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[6]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[8]</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any 2 antigens</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All 3 antigens</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="135"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Neutralizing Antibody Responses 4 Weeks After the Second Vaccination</title>
        <description>Neutralizing antibody response was defined as a ≥ 2.7-fold rise in antibody titer between Baseline and 28 days after the second injection (Day 56). Neutralizing antibodies to each of the three rotavirus strains from which the vaccine antigens were derived (Wa, DS-1, and 1076) were measured using a validated assay. For infants, antibody titers were adjusted for decay in maternal antibodies.</description>
        <time_frame>Day 56, prevaccination</time_frame>
        <population>Per-protocol population, participants with available data for each strain</population>
        <group_list>
          <group group_id="O1">
            <title>Infants: Placebo</title>
            <description>Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Infants: 15 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Infants: 30 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Infants: 90 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Neutralizing Antibody Responses 4 Weeks After the Second Vaccination</title>
          <description>Neutralizing antibody response was defined as a ≥ 2.7-fold rise in antibody titer between Baseline and 28 days after the second injection (Day 56). Neutralizing antibodies to each of the three rotavirus strains from which the vaccine antigens were derived (Wa, DS-1, and 1076) were measured using a validated assay. For infants, antibody titers were adjusted for decay in maternal antibodies.</description>
          <population>Per-protocol population, participants with available data for each strain</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rotavirus strain Wa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rotavirus strain DS-1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rotavirus strain 1076</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any 2 strains</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All 3 strains</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adults and Toddlers With Anti-P2-VP8 Immunoglobulin G (IgG) Seroresponse, by Vaccine Antigen</title>
        <description>Seroresponse was defined as a four-fold rise or greater in IgG antibody titer between Baseline and 28 days after the final injection (Day 84 for adults and Day 28 for toddlers). Measured by enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Day 84 for adults; Day 28 for toddlers</time_frame>
        <population>Per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Adults: Placebo</title>
            <description>Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Adults: 30 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Adults: 90 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Toddlers: Placebo</title>
            <description>Toddlers received one intramuscular injection of placebo on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Toddlers: 30 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>Toddlers: 90 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adults and Toddlers With Anti-P2-VP8 Immunoglobulin G (IgG) Seroresponse, by Vaccine Antigen</title>
          <description>Seroresponse was defined as a four-fold rise or greater in IgG antibody titer between Baseline and 28 days after the final injection (Day 84 for adults and Day 28 for toddlers). Measured by enzyme-linked immunosorbent assay (ELISA).</description>
          <population>Per-protocol population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P[4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any 2 antigens</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All 3 antigens</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adults and Toddlers With Anti-P2-VP8 Immunoglobulin A (IgA) Seroresponse, by Vaccine Antigen</title>
        <description>Seroresponse was defined as a four-fold rise or greater in IgA antibody titer between Baseline and 28 days after the final injection (Day 84 for adults and Day 28 for toddlers). Measured by enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Day 84 for adults; Day 28 for toddlers</time_frame>
        <population>Per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Adults: Placebo</title>
            <description>Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Adults: 30 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Adults: 90 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Toddlers: Placebo</title>
            <description>Toddlers received one intramuscular injection of placebo on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Toddlers: 30 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>Toddlers: 90 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adults and Toddlers With Anti-P2-VP8 Immunoglobulin A (IgA) Seroresponse, by Vaccine Antigen</title>
          <description>Seroresponse was defined as a four-fold rise or greater in IgA antibody titer between Baseline and 28 days after the final injection (Day 84 for adults and Day 28 for toddlers). Measured by enzyme-linked immunosorbent assay (ELISA).</description>
          <population>Per-protocol population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P[4]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[8]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any 2 antigens</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All 3 antigens</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adults and Toddlers With Neutralizing Antibody Responses to Each Rotavirus Strain</title>
        <description>Neutralizing antibody response was defined as a ≥ 2.7-fold rise in antibody titer between Baseline and 28 days after the final injection (Day 84 for adults and Day 28 for toddlers) for each of the three rotavirus strains from which the vaccine antigens were derived (Wa, DS-1, and 1076).</description>
        <time_frame>Day 84 for adults; Day 28 for toddlers</time_frame>
        <population>Per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Adults: Placebo</title>
            <description>Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Adults: 30 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Adults: 90 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Toddlers: Placebo</title>
            <description>Toddlers received one intramuscular injection of placebo on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Toddlers: 30 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>Toddlers: 90 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adults and Toddlers With Neutralizing Antibody Responses to Each Rotavirus Strain</title>
          <description>Neutralizing antibody response was defined as a ≥ 2.7-fold rise in antibody titer between Baseline and 28 days after the final injection (Day 84 for adults and Day 28 for toddlers) for each of the three rotavirus strains from which the vaccine antigens were derived (Wa, DS-1, and 1076).</description>
          <population>Per-protocol population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rotavirus strain Wa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rotavirus strain DS-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rotavirus strain 1076</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any 2 strains</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All 3 strains</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-P2-VP8 Immunoglobulin G (IgG) Geometric Mean Titers Among Adults and Toddlers, by Vaccine Antigen</title>
        <description>Measured at Baseline and 28 days after the final injection (Day 84 for adults; Day 28 for toddlers).</description>
        <time_frame>Baseline and Day 28 for toddlers or Day 84 for adults</time_frame>
        <population>Per protocol population; participants with valid specimens at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults: Placebo</title>
            <description>Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Adults: 30 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Adults: 90 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Toddlers: Placebo</title>
            <description>Toddlers received one intramuscular injection of placebo on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Toddlers: 30 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>Toddlers: 90 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-P2-VP8 Immunoglobulin G (IgG) Geometric Mean Titers Among Adults and Toddlers, by Vaccine Antigen</title>
          <description>Measured at Baseline and 28 days after the final injection (Day 84 for adults; Day 28 for toddlers).</description>
          <population>Per protocol population; participants with valid specimens at each time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P[4]: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425" lower_limit="198" upper_limit="909"/>
                    <measurement group_id="O2" value="358" lower_limit="215" upper_limit="596"/>
                    <measurement group_id="O3" value="444" lower_limit="314" upper_limit="627"/>
                    <measurement group_id="O4" value="183" lower_limit="64" upper_limit="523"/>
                    <measurement group_id="O5" value="195" lower_limit="89" upper_limit="425"/>
                    <measurement group_id="O6" value="282" lower_limit="124" upper_limit="642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[4]: 28 days post-final vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311" lower_limit="84" upper_limit="1156"/>
                    <measurement group_id="O2" value="11642" lower_limit="7560" upper_limit="17927"/>
                    <measurement group_id="O3" value="13337" lower_limit="8229" upper_limit="21616"/>
                    <measurement group_id="O4" value="174" lower_limit="57" upper_limit="527"/>
                    <measurement group_id="O5" value="920" lower_limit="285" upper_limit="2974"/>
                    <measurement group_id="O6" value="2396" lower_limit="1089" upper_limit="5274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[6]: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="34" upper_limit="232"/>
                    <measurement group_id="O2" value="251" lower_limit="90" upper_limit="695"/>
                    <measurement group_id="O3" value="234" lower_limit="101" upper_limit="541"/>
                    <measurement group_id="O4" value="58" lower_limit="20" upper_limit="165"/>
                    <measurement group_id="O5" value="172" lower_limit="65" upper_limit="457"/>
                    <measurement group_id="O6" value="150" lower_limit="86" upper_limit="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[6]: 28 days post-final vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="14" upper_limit="576"/>
                    <measurement group_id="O2" value="22120" lower_limit="12905" upper_limit="37916"/>
                    <measurement group_id="O3" value="29706" lower_limit="17801" upper_limit="49573"/>
                    <measurement group_id="O4" value="72" lower_limit="27" upper_limit="192"/>
                    <measurement group_id="O5" value="1767" lower_limit="468" upper_limit="6672"/>
                    <measurement group_id="O6" value="2515" lower_limit="884" upper_limit="7158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[8]: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140" lower_limit="39" upper_limit="509"/>
                    <measurement group_id="O2" value="205" lower_limit="109" upper_limit="387"/>
                    <measurement group_id="O3" value="220" lower_limit="126" upper_limit="386"/>
                    <measurement group_id="O4" value="229" lower_limit="70" upper_limit="751"/>
                    <measurement group_id="O5" value="113" lower_limit="42" upper_limit="416"/>
                    <measurement group_id="O6" value="231" lower_limit="73" upper_limit="731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[8]: 28 days post-final vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" lower_limit="24" upper_limit="529"/>
                    <measurement group_id="O2" value="11355" lower_limit="7138" upper_limit="18063"/>
                    <measurement group_id="O3" value="14557" lower_limit="8892" upper_limit="23831"/>
                    <measurement group_id="O4" value="294" lower_limit="70" upper_limit="1239"/>
                    <measurement group_id="O5" value="1207" lower_limit="389" upper_limit="3749"/>
                    <measurement group_id="O6" value="4059" lower_limit="2022" upper_limit="8149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-P2-VP8 Immunoglobulin A (IgA) Geometric Mean Titers Among Adults and Toddlers, by Vaccine Antigen</title>
        <description>Measured at Baseline and 28 days after the final injection (Day 84 for adults; Day 28 for toddlers).</description>
        <time_frame>Baseline and Day 28 for toddlers or Day 84 for adults</time_frame>
        <population>Per-protocol population participants with valid specimens at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults: Placebo</title>
            <description>Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Adults: 30 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Adults: 90 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Toddlers: Placebo</title>
            <description>Toddlers received one intramuscular injection of placebo on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Toddlers: 30 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>Toddlers: 90 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-P2-VP8 Immunoglobulin A (IgA) Geometric Mean Titers Among Adults and Toddlers, by Vaccine Antigen</title>
          <description>Measured at Baseline and 28 days after the final injection (Day 84 for adults; Day 28 for toddlers).</description>
          <population>Per-protocol population participants with valid specimens at each time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P[4]: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151" lower_limit="34" upper_limit="676"/>
                    <measurement group_id="O2" value="186" lower_limit="78" upper_limit="445"/>
                    <measurement group_id="O3" value="143" lower_limit="69" upper_limit="297"/>
                    <measurement group_id="O4" value="174" lower_limit="32" upper_limit="936"/>
                    <measurement group_id="O5" value="124" lower_limit="45" upper_limit="338"/>
                    <measurement group_id="O6" value="49" lower_limit="18" upper_limit="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[4]: 28 days post-final vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202" lower_limit="15" upper_limit="2654"/>
                    <measurement group_id="O2" value="4685" lower_limit="1395" upper_limit="15734"/>
                    <measurement group_id="O3" value="4533" lower_limit="1990" upper_limit="10326"/>
                    <measurement group_id="O4" value="221" lower_limit="55" upper_limit="897"/>
                    <measurement group_id="O5" value="629" lower_limit="204" upper_limit="1935"/>
                    <measurement group_id="O6" value="443" lower_limit="180" upper_limit="1091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[6]: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="25" upper_limit="127"/>
                    <measurement group_id="O2" value="120" lower_limit="56" upper_limit="257"/>
                    <measurement group_id="O3" value="113" lower_limit="43" upper_limit="296"/>
                    <measurement group_id="O4" value="16" lower_limit="5" upper_limit="49"/>
                    <measurement group_id="O5" value="55" lower_limit="22" upper_limit="137"/>
                    <measurement group_id="O6" value="15" lower_limit="9" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[6]: 28 days post-final vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="38" upper_limit="236"/>
                    <measurement group_id="O2" value="2470" lower_limit="796" upper_limit="7659"/>
                    <measurement group_id="O3" value="1864" lower_limit="505" upper_limit="6886"/>
                    <measurement group_id="O4" value="15" lower_limit="4" upper_limit="65"/>
                    <measurement group_id="O5" value="198" lower_limit="69" upper_limit="569"/>
                    <measurement group_id="O6" value="101" lower_limit="37" upper_limit="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[8]: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119" lower_limit="23" upper_limit="614"/>
                    <measurement group_id="O2" value="151" lower_limit="60" upper_limit="380"/>
                    <measurement group_id="O3" value="89" lower_limit="40" upper_limit="201"/>
                    <measurement group_id="O4" value="136" lower_limit="14" upper_limit="1294"/>
                    <measurement group_id="O5" value="83" lower_limit="24" upper_limit="293"/>
                    <measurement group_id="O6" value="41" lower_limit="13" upper_limit="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P[8]: 28 days post-final vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194" lower_limit="19" upper_limit="2010"/>
                    <measurement group_id="O2" value="3590" lower_limit="1060" upper_limit="12156"/>
                    <measurement group_id="O3" value="2350" lower_limit="766" upper_limit="7210"/>
                    <measurement group_id="O4" value="211" lower_limit="18" upper_limit="2480"/>
                    <measurement group_id="O5" value="928" lower_limit="324" upper_limit="2653"/>
                    <measurement group_id="O6" value="530" lower_limit="211" upper_limit="1333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Neutralizing Antibody Against Rotavirus Strains Among Adults and Toddlers</title>
        <description>Measured at Baseline and 28 days after the final injection (Day 84 for adults; Day 28 for toddlers).</description>
        <time_frame>Baseline and Day 28 for toddlers or Day 84 for adults</time_frame>
        <population>Per-protocol population participants with valid specimens at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults: Placebo</title>
            <description>Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Adults: 30 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Adults: 90 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Toddlers: Placebo</title>
            <description>Toddlers received one intramuscular injection of placebo on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Toddlers: 30 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
          <group group_id="O6">
            <title>Toddlers: 90 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Neutralizing Antibody Against Rotavirus Strains Among Adults and Toddlers</title>
          <description>Measured at Baseline and 28 days after the final injection (Day 84 for adults; Day 28 for toddlers).</description>
          <population>Per-protocol population participants with valid specimens at each time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain Wa: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317" lower_limit="123" upper_limit="820"/>
                    <measurement group_id="O2" value="448" lower_limit="247" upper_limit="815"/>
                    <measurement group_id="O3" value="276" lower_limit="193" upper_limit="396"/>
                    <measurement group_id="O4" value="77" lower_limit="16" upper_limit="369"/>
                    <measurement group_id="O5" value="131" lower_limit="46" upper_limit="373"/>
                    <measurement group_id="O6" value="67" lower_limit="25" upper_limit="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain Wa: 28 days post-final vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244" lower_limit="80" upper_limit="743"/>
                    <measurement group_id="O2" value="913" lower_limit="579" upper_limit="1439"/>
                    <measurement group_id="O3" value="815" lower_limit="531" upper_limit="1251"/>
                    <measurement group_id="O4" value="78" lower_limit="16" upper_limit="370"/>
                    <measurement group_id="O5" value="147" lower_limit="47" upper_limit="459"/>
                    <measurement group_id="O6" value="253" lower_limit="119" upper_limit="537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain DS-1: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="16" upper_limit="355"/>
                    <measurement group_id="O2" value="114" lower_limit="57" upper_limit="228"/>
                    <measurement group_id="O3" value="119" lower_limit="57" upper_limit="248"/>
                    <measurement group_id="O4" value="16" lower_limit="3" upper_limit="85"/>
                    <measurement group_id="O5" value="29" lower_limit="9" upper_limit="92"/>
                    <measurement group_id="O6" value="20" lower_limit="9" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain DS-1: 28 days post-final vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="4" upper_limit="813"/>
                    <measurement group_id="O2" value="390" lower_limit="278" upper_limit="545"/>
                    <measurement group_id="O3" value="317" lower_limit="152" upper_limit="659"/>
                    <measurement group_id="O4" value="15" lower_limit="3" upper_limit="79"/>
                    <measurement group_id="O5" value="40" lower_limit="14" upper_limit="113"/>
                    <measurement group_id="O6" value="60" lower_limit="22" upper_limit="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain 1076: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="14" upper_limit="415"/>
                    <measurement group_id="O2" value="175" lower_limit="74" upper_limit="416"/>
                    <measurement group_id="O3" value="152" lower_limit="63" upper_limit="366"/>
                    <measurement group_id="O4" value="13" lower_limit="3" upper_limit="53"/>
                    <measurement group_id="O5" value="28" lower_limit="9" upper_limit="89"/>
                    <measurement group_id="O6" value="16" lower_limit="8" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain 1076: 28 days post-final vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="4" upper_limit="428"/>
                    <measurement group_id="O2" value="354" lower_limit="180" upper_limit="695"/>
                    <measurement group_id="O3" value="284" lower_limit="132" upper_limit="607"/>
                    <measurement group_id="O4" value="15" lower_limit="3" upper_limit="67"/>
                    <measurement group_id="O5" value="30" lower_limit="9" upper_limit="99"/>
                    <measurement group_id="O6" value="25" lower_limit="11" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Adults and Infants With ≥ 4-fold Rise in Neutralizing Antibody Titer to Each Rotavirus Strain</title>
        <description>The number of adults and infants with a 4-fold or greater increase from Baseline in neutralizing antibody titers to each of the three rotavirus strains from which the vaccine antigens were derived 4 weeks after the second (Day 56) and third (Day 84) vaccinations.
For infants, antibody titer was adjusted for decay in maternal antibodies.</description>
        <time_frame>Day 56 and Day 84</time_frame>
        <population>Per-protocol population participants with valid specimens at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults: Placebo</title>
            <description>Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O2">
            <title>Adults: 30 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O3">
            <title>Adults: 90 µg P2-VP8</title>
            <description>Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O4">
            <title>Infants: Placebo</title>
            <description>Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O5">
            <title>Infants: 15 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O6">
            <title>Infants: 30 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
          <group group_id="O7">
            <title>Infants: 90 µg P2-VP8</title>
            <description>Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adults and Infants With ≥ 4-fold Rise in Neutralizing Antibody Titer to Each Rotavirus Strain</title>
          <description>The number of adults and infants with a 4-fold or greater increase from Baseline in neutralizing antibody titers to each of the three rotavirus strains from which the vaccine antigens were derived 4 weeks after the second (Day 56) and third (Day 84) vaccinations.
For infants, antibody titer was adjusted for decay in maternal antibodies.</description>
          <population>Per-protocol population participants with valid specimens at each time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="137"/>
                <count group_id="O6" value="132"/>
                <count group_id="O7" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain Wa: Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="135"/>
                    <count group_id="O5" value="137"/>
                    <count group_id="O6" value="131"/>
                    <count group_id="O7" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="29"/>
                    <measurement group_id="O7" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain Wa: Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="130"/>
                    <count group_id="O5" value="132"/>
                    <count group_id="O6" value="132"/>
                    <count group_id="O7" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="73"/>
                    <measurement group_id="O6" value="95"/>
                    <measurement group_id="O7" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain DS-1: Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="134"/>
                    <count group_id="O5" value="137"/>
                    <count group_id="O6" value="131"/>
                    <count group_id="O7" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain DS-1: Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="130"/>
                    <count group_id="O5" value="131"/>
                    <count group_id="O6" value="132"/>
                    <count group_id="O7" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="85"/>
                    <measurement group_id="O6" value="96"/>
                    <measurement group_id="O7" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain 1076: Day 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="135"/>
                    <count group_id="O5" value="137"/>
                    <count group_id="O6" value="131"/>
                    <count group_id="O7" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain 1076: Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="130"/>
                    <count group_id="O5" value="132"/>
                    <count group_id="O6" value="132"/>
                    <count group_id="O7" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="73"/>
                    <measurement group_id="O6" value="86"/>
                    <measurement group_id="O7" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Toddlers With ≥ 4-fold Rise in Neutralizing Antibody Titer to Each Rotavirus Strain</title>
        <description>The number of toddlers with a 4-fold or greater increase from Baseline 4 weeks after vaccination in neutralizing antibody titers to each of the three rotavirus strains from which the vaccine antigens were derived.</description>
        <time_frame>Day 28</time_frame>
        <population>Per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Toddlers: Placebo</title>
            <description>Toddlers received one intramuscular injection of placebo on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Toddlers: 30 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Toddlers: 90 µg P2-VP8</title>
            <description>Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Toddlers With ≥ 4-fold Rise in Neutralizing Antibody Titer to Each Rotavirus Strain</title>
          <description>The number of toddlers with a 4-fold or greater increase from Baseline 4 weeks after vaccination in neutralizing antibody titers to each of the three rotavirus strains from which the vaccine antigens were derived.</description>
          <population>Per-protocol population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rotavirus strain Wa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rotavirus strain DS-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rotavirus strain 1076</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 months after the last injection (224 days for adults and infants; 168 days for toddlers)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adult: Placebo</title>
          <description>Adult participants who received three intramuscular injections of placebo four weeks apart on days 0, 28, and 56. Approximately half of the participants were compared to the arm receiving the 30 µg dose of P2-VP8; once the safety of this dose was established, the other half were compared to the arm receiving 90 µg.</description>
        </group>
        <group group_id="E2">
          <title>Adult: P2-VP8 (30 µg)</title>
          <description>Adult participants who received three intramuscular injections of Trivalent P2-VP8 Subunit Rotavirus Vaccine (30 µg) four weeks apart on days 0, 28, and 56.</description>
        </group>
        <group group_id="E3">
          <title>Adult: P2-VP8 (90 µg)</title>
          <description>Adult participants who received three intramuscular injections of Trivalent P2-VP8 Subunit Rotavirus Vaccine (90 µg) four weeks apart on days 0, 28, and 56.</description>
        </group>
        <group group_id="E4">
          <title>Toddler: Placebo</title>
          <description>Toddler participants who received one intramuscular injection of placebo on day 0. Approximately half of the participants were compared to the arm receiving the 30 µg dose of P2-VP8; once the safety of this dose was established, the other half were compared to the arm receiving 90 µg.</description>
        </group>
        <group group_id="E5">
          <title>Toddler: P2-VP8 (30 µg)</title>
          <description>Toddler participants who received one intramuscular injections of Trivalent P2-VP8 Subunit Rotavirus Vaccine (30 µg) on day 0.</description>
        </group>
        <group group_id="E6">
          <title>Toddler: P2-VP8 (90 µg)</title>
          <description>Toddler participants who received one intramuscular injection of Trivalent P2-VP8 Subunit Rotavirus Vaccine (90 µg) on day 0.</description>
        </group>
        <group group_id="E7">
          <title>Infant: Placebo</title>
          <description>Infant participants who received three intramuscular injections of placebo four weeks apart on days 0, 28, and 56. Approximately one third of the participants were compared to the arm receiving the 15 µg dose of P2-VP8; once the safety of the 15 µg dose was established, one third of the participants were compared to the arm receiving 30 µg; and the last third were compared to the arm receiving 90 µg after the safety of the 30 µg dose was established.</description>
        </group>
        <group group_id="E8">
          <title>Infant: P2-VP8 (15 µg)</title>
          <description>Infant participants who received three intramuscular injections of Trivalent P2-VP8 Subunit Rotavirus Vaccine (15 µg) four weeks apart on days 0, 28, and 56.</description>
        </group>
        <group group_id="E9">
          <title>Infant: P2-VP8 (30 µg)</title>
          <description>Infant participants who received three intramuscular injections of Trivalent P2-VP8 Subunit Rotavirus Vaccine (30 µg) four weeks apart on days 0, 28, and 56.</description>
        </group>
        <group group_id="E10">
          <title>Infant: P2-VP8 (90 µg)</title>
          <description>Infant participants who received three intramuscular injections of Trivalent P2-VP8 Subunit Rotavirus Vaccine (90 µg) four weeks apart on days 0, 28, and 56.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess soft tissue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Meningitis pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="132" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="129" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="134" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="130" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="26" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="22" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Oral mucosal blistering</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="20" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="19" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Candida nappy rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="14" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Coxsackie viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Ophthalmia neonatorum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="27" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="29" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Tinea faciei</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="70" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="84" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="74" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="82" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Vaccination site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Exposure to communicable disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Poor feeding infant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Weight gain poor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Penile swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="17" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="34" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="24" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="47" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="16" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="19" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Eczema infantile</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Milia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pityriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pityriasis alba</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="14" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="17" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Skin depigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Flores</name_or_title>
      <organization>PATH</organization>
      <phone>(202) 822-0033</phone>
      <email>jeflores@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

